SHH · 600351.SS
Yabao Pharmaceutical Group Co., Ltd
CN¥7.18+CN¥0.08 (+1.13%)
Yabao Pharmaceutical Group Co., Ltd’s quoted price sits in the upper half of its reported 52-week range, 3.62% below the high.
Loading market information…
SHH · 603538.SS · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:15 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Ningbo Menovo Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 58.81% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Ningbo Menovo Pharmaceutical Co., Ltd.’s forward annual dividend is CN¥0.16 per share, paid annual. The forward yield is 0.75% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Ningbo Menovo Pharmaceutical Co., Ltd.’s next earnings report is currently expected on Oct 30, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Ningbo Menovo Pharmaceutical Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Ningbo Menovo Pharmaceutical Co., Ltd. operates across the full spectrum of pharmaceutical activities, encompassing the research, development, production, and distribution of medicinal products. Their extensive product line features Active Pharmaceutical Ingredients (APIs), intermediate chemicals, and finished drug formulations. These offerings are designed to address a wide range of therapeutic areas, including cardiovascular, central nervous system, respiratory, oncological, anti-infective, digestive, and geriatric disorders, as well as antiviral treatments. The company commenced operations in 2004 and maintains its principal place of business in Ningbo, China.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:31 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
KEEP COMPARING
CN¥7.18+CN¥0.08 (+1.13%)
Yabao Pharmaceutical Group Co., Ltd’s quoted price sits in the upper half of its reported 52-week range, 3.62% below the high.
CN¥8.52-CN¥0.04 (-0.47%)
HPGC Renmintongtai Pharmaceutical Corporation’s quoted price sits in the lower half of its reported 52-week range, 53.01% below the high.
CN¥8.16+CN¥0.17 (+2.13%)
Beijing Beilu Pharmaceutical Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 28.38% below the high.
CN¥8.74+CN¥0.19 (+2.22%)
Teyi Pharmaceutical Group Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 42.47% below the high.
CN¥10.06+CN¥0.29 (+2.97%)
Hunan Fangsheng Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.63% below the high.
CN¥3.58+CN¥0.03 (+0.85%)
Fuan Pharmaceutical (Group) Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 28.4% below the high.
CN¥4.59-CN¥0.05 (-1.08%)
Jinhe Biotechnology Co. Ltd.’s quoted price sits in the lower half of its reported 52-week range, 34.43% below the high.
CN¥7.40-CN¥0.01 (-0.13%)
LanZhou Foci Pharmaceutical Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 32.85% below the high.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
